Enrolling by invitationPhase 4NCT06660329
Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
Studying Blau syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking Union Medical College Hospital
- Intervention
- Janus Kinase Inhibitor(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 0-18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- Peking Union Medical College Hospital, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06660329 on ClinicalTrials.govOther trials for Blau syndrome
Additional recruiting or active studies for the same condition.